Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference

President and CEO Sean Bohen said the company believes the emerging oral selective estrogen receptor degrader (SERD) class has proven its value over the past year, even as many earlier candidates fell ...

Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit

CEO Sean Bohen outlined the company’s focus on advancing endocrine therapies for ER-positive, HER2-negative breast cancer ...

How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors

In recent months, Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, who will remain as a consultant through August 1, 2026, while advancing late-stage trials for its lead ...
Business Insider

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile ...
Seeking Alpha

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with ...

SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (OLMA) (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...
Nasdaq

Olema Oncology presents updated results for palazestrant

Olema Pharmaceuticals announced updated clinical results from the ongoing Phase 1b/2 study of palazestrant in combination with CDK4/6 inhibitor, ribociclib, in patients with estrogen receptor-positive ...

Olema earnings on deck: Biotech faces widening loss ahead of key data

Olema Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing therapies for metastatic breast cancer, is set to report fourth-quarter results on Monday, March 2, during market ...
Nasdaq

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...
manilatimes

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In ...
Business Insider

Buy Rating for Olema Pharmaceuticals: Promising Progress in Palazestrant and Ribociclib Breast Cancer Trial

Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained the rating on the stock ...
ascopubs.org

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for patients with ER+, HER2- advanced or metastatic breast cancer after ...

Exploring depression risk among breast cancer survivors: A nationwide cohort study in South Korea. An exploratory investigator-initiated trial via intrathecal or intracerebroventricular delivery of ...